Logo

Ultragenyx's Dojolvi (UX007/triheptanoin) Receives the US FDA's Approval to Treat Long-Chain Fatty Acid Oxidation Disorders

Share this

Ultragenyx's Dojolvi (UX007/triheptanoin) Receives the US FDA's Approval to Treat Long-Chain Fatty Acid Oxidation Disorders

Shots:

  • Ultragenyx is a highly purified- pharmaceutical-grade- odd-carbon medium-chain triglyceride consisting of three 7-carbon fatty acids on a glycerol backbone created via a multi-step chemical process
  • The FDA approved Dojolvi as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD)
  • The company expects its availability in the next 30 days while for its access the Ultragenyx’s UltraCare program will help patients and caregivers to understand insurance coverage and assist them in finding financial support for Ultragenyx medicines

Ref: Ultragenyx | Image: Behance

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions